1(3H)-Isobenzofuranone, 3-butyl-4-hydroxy-, (S)- | 74459-24-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 1(3H)-Isobenzofuranone, 3-butyl-4-hydroxy-, (S)-
• 英文别名: (3S)-3-butyl-4-hydroxy-3H-2-benzofuran-1-one
• CAS: 74459-24-8
• 化学式: C₁₂H₁₄O₃
• 分子量: 206.24
• InChiKey: JQSVHBFDZXZENO-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Anti-tumor traditional Chinese medicine microbial fermentation preparation and a preparation method and application thereof
  申请人：Li Xingyao

  公开号：US10987389B2

  公开（公告）日：2021-04-27

  An anti-tumor traditional Chinese medicine, a preparation method therefor, and uses thereof. This traditional Chinese medicine is prepared by leavening of Pleurotus sp. and Dioscorea bulbifera, pangolin scales, rhubarb, oyster, stiff silkworm, kelp, selfheal, Ligusticum wallichii, barbat skullcap, honeysuckle flower, Oldenlandia diffusa, Radix trichosanthis, Rhizoma anemarrhenae Scutellaria baicalensis, Angelica sinensis, Psoralea corylifolia, Lucid ganoderma, and coix seed.

  一种抗肿瘤中药、其制备方法及其用途。这种中药是由浙贝母、穿山甲、大黄、牡蛎、僵蚕、海带等发酵而成。和薯蓣、穿山甲鳞片、大黄、牡蛎、僵蚕、海带、自愈菜、藁本、巴豆、金银花、老鹳草、三七、黄芩、当归、车前子、灵芝、薏苡仁发酵而成。
• USE OF PHTHALIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES MELLITUS
  申请人：DSM IP Assets B.V.

  公开号：EP1622605B1

  公开（公告）日：2009-07-15
• Use of phthalide derivatives for the treatment and prevention of diabetes mellitus
  申请人：D'Orazio Daniel

  公开号：US20070082947A1

  公开（公告）日：2007-04-12

  The present invention relates to the use of a compound as effective agent for the prevention or treatment of diabetes mellitus in a mammal. Said compounds being selected from the group of phthalide derivatives and exhibit excellent blood glucose lowering effects and thus are effective agents in the prevention or treatment of diabetes mellitus in mammals.
• NOVEL USE OF ORGANIC COMPOUNDS
  申请人：Fowler Ann

  公开号：US20090176873A1

  公开（公告）日：2009-07-09

  The present invention relates to the use of compounds of the formula (I) wherein the clotted line is an optional bond; R 1 is butyl or butyryl if R 2 is hydroxyl but is butyl if R 2 is hydrogen; or R 1 and R 2 taken together are 1-butylidene optionally substituted by hydroxyl, methyl, or 3-(α,β-dimethylacrylyloxy)-pentylidenyl; X is a residue selected from the group consisting of X1, X2, X3, X4, and X5; wherein X is X2, X3 or X5 if the dotted line in formula (I) is absent; and X is X1, X4 or X5 if the dotted line signifies a bond in formula (I) above; R 3 is hydroxyl or butyryl; and n is 1 or 2, as agents for the prevention, control and treatment of conditions requiring modulation of inflammation in mammals. In another aspect, the present invention relates to the use of compounds of the formula (I) as active ingredients in the manufacture of medicaments/compositions for the prevention, control and treatment of conditions requiring modulation of inflammation. The compounds of formula (I) as defined above may also be useful (for the manufacture of a composition) for the management of pain, fever and injuries, especially sport injuries. Moreover, the compounds of formula (I) as defined above may also be useful (for the manufacture of a composition) for the maintenance and regeneration of articular cartilage.
• ORGANIC COMPOUNDS FOR TREATMENT OF DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION
  申请人：De Saizieu Antoine

  公开号：US20100184852A1

  公开（公告）日：2010-07-22

  The present invention refers to compounds of the general formula (I) wherein R 1 is hydrogen or hydroxy; R 2 is butyl or butyryl if R 1 is hydroxy, but R 2 is butyl if R 1 is hydrogen; or R 3 and R 2 taken together are 1-propylidene or 1-butylidene optionally substituted by hydroxy, methyl, or 3-(α, β-dimethylacryloyloxy); the dotted line is an optional bond; X is an optionally substituted aliphatic C4-residue selected from the group consisting of X1, X2, X3, X4, and X5; wherein X is X2, X3 or X5 if the dotted line in formula (I) is absent; and X is X1, X4 or X5 if the dotted line signifies a bond in formula (I) above; R 3 and R 4 are, independently from each other, hydrogen or hydroxy; and R 5 is hydroxy or butyryl, for use in the treatment of disorders connected to impaired neurotransmission, as well as to dietary and pharmaceutical compositions containing such compounds, and their uses.